Master protocol to assess safety and recommended phase 2 dose of next generation NY-ESO-1–specific TCR T-cells in HLA-A*02 patients with synovial sarcoma or non-small cell lung cancer (Substudies 1 and 2).

Adam J. Schoenfeld,Mehmet Altan,Taofeek K. Owonikoko,Sandra P. DAngelo,Brian H. Ladle,Jonathan Christopher Noujaim,Kai He,David A. Liebner,Adrian G. Sacher,John B. A. G. Haanen,Jeffrey Yachnin,Chao H. Huang,Brian A. Van Tine,Aisha N. Hasan,Faitg Thomas H,Emily Butler,Aiman Shalabi,Steven Attia,Dejka M. Araujo

Master protocol to assess safety and recommended phase 2 dose of next generation NY-ESO-1–specific TCR T-cells in HLA-A*02 patients with synovial sarcoma or non-small cell lung cancer (Substudies 1 and 2).

2021

Adam J. Schoenfeld
Mehmet Altan
Taofeek K. Owonikoko
Sandra P. DAngelo
Brian H. Ladle
Jonathan Christopher Noujaim
Kai He
David A. Liebner
Adrian G. Sacher
John B. A. G. Haanen
Jeffrey Yachnin
Chao H. Huang
Brian A. Van Tine
Aisha N. Hasan
Faitg Thomas H
Emily Butler
Aiman Shalabi
Steven Attia
Dejka M. Araujo

TPS2661Background: Letetresgene autoleucel (lete-cel; GSK3377794) is an autologous T-cell therapy using a genetically modified T-cell receptor (TCR) to improve recognition of cancer cells expressin...

Keywords:

Medicine
Lung cancer
Synovial sarcoma
Genetically modified organism
NY-ESO-1
Receptor
Cancer research
HLA-A
T-cell receptor
Cancer cell

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations